Navigation
SEARCH

Key Multiplicity Issues in Clinical Trials DIA 2013

From MultXpert

(Difference between revisions)
Jump to: navigation, search
(Created page with 'Selected presentations given at the Drug Information Association (DIA) Annual Meeting in Boston, MA on May 24-26, 2013. === Key multiplicity concepts and principles addressed in…')
m
 
Line 7: Line 7:
Download [http://www.multxpert.com/doc/dia2013a.pdf slides].
Download [http://www.multxpert.com/doc/dia2013a.pdf slides].
-
=== Key statistical considerations for clinical trials with tailoring objectives ===
+
=== Key multiplicity issues in clinical drug development ===
-
Presented by Alex Dmitrienko, Executive Director, Quintiles (jointly with Brian Millen, Eli Lilly and Company).
+
Presented by Ralph D'Agostino, Boston University.
-
Download [http://www.multxpert.com/doc/dia2013b.pdf slides].
+
Slides will be uploaded soon.
=== Analysis of clinical trials with multiple objectives ===
=== Analysis of clinical trials with multiple objectives ===

Current revision as of 02:44, 6 July 2013

Selected presentations given at the Drug Information Association (DIA) Annual Meeting in Boston, MA on May 24-26, 2013.

Key multiplicity concepts and principles addressed in the draft guidance "Multiple Endpoints in Clinical Trials"

Presented by Mohammad Huque, Director, Division of Biometrics IV, Office of Biostatistics, Office of the Translational Sciences, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration.

Download slides.

Key multiplicity issues in clinical drug development

Presented by Ralph D'Agostino, Boston University.

Slides will be uploaded soon.

Analysis of clinical trials with multiple objectives

Presented by Alex Dmitrienko, Executive Director, Quintiles.

Download slides.